ICU Medical (STU:IC7) Moat Score: 5/10 (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IC7 ICU Medical Inc STU:IC7
80 GF Score
Price €158.00
GF Value €105.79
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is ICU Medical Moat Score?

ICU Medical STU:IC7 80 Moat Score is 5 as of Aug. 17, 2026. GuruFocus rates STU:IC7 with a GF Score™ of 80/100 and a GF Value™ of €105.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 835 Medical Devices & Instruments companies, ICU Medical ranks better than 91.14% on this metric.

ICU Medical has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

ICU Medical has Narrow Moat: ICUI has a solid market position in the medical device industry with some proprietary technology and customer loyalty. However, it lacks the scale and regulatory barriers needed for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes ICU Medical might have Narrow Moat - Solid narrow moat.

ICU Medical  (STU:IC7) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

ICU Medical Moat Score Related Terms

STU:IC7 vs NVST, MMSI, MMED: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, ICU Medical's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ICU Medical Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's Moat Score distribution charts can be found below:

* The bar in red indicates where ICU Medical's Moat Score falls into.


STU:IC7
80GF Score
ICU Medical Inc STU:IC7
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
ICU Medical (STU:IC7) has a Moat Score of 5 as of Aug. 17, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, ICU Medical ranks #74 out of 835 companies in the Medical Devices & Instruments industry, placing it in the top 8.9%.
Is ICU Medical's Moat Score too high?
ICU Medical's current Moat Score is 5. Based on the distribution chart, ICU Medical ranks #74 out of 835 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ICU Medical has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's Moat Score compare to NVST and MMSI?
According to the Medical Devices & Instruments industry distribution chart, ICU Medical ranks #74 out of 835 companies for Moat Score. This places ICU Medical in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. ICU Medical's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (STU:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €105.79, compared to a current price of €158.00 — trading 49.4% above its estimated fair value. The current Moat Score is 5. ICU Medical's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For ICU Medical (STU:IC7), the current Moat Score is 5 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ICU Medical (STU:IC7) Overvalued in 2026?

Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued. The current stock price of €158.00 is trading 49.4% above its estimated GF Value™ of €105.79. GuruFocus considers ICU Medical to be Significantly Overvalued.

Key valuation signals for STU:IC7:

  • Moat Score: 5
  • GF Value™: €105.79 vs. price of €158.00 (49.4% above fair value)
  • GF Score™: 80/100 with 8 warning signs

No single metric tells the full story. See the STU:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ICU Medical Business Description

Other Exchanges ICUI:USA
Address 951 Calle Amanecer, San Clemente, CA, USA, 92673
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
80GF Score

Get the complete analysis for STU:IC7

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€158.00
Price
€105.79
GF Value